期刊文献+

基于非线性控制模型的药物动力学的问题研究

Research on Questions of Pharmacokinetic Based on Nonlinear Control Model
下载PDF
导出
摘要 在临床和临床前的研究中,确定最大的可允许的剂量水平可以避免化学药品导致的毒性.通过血流灌注限制性的消除隔室模型,完成对药物在人体中处置过程的预测,并能得到机体功能的生理或病理改变所引起的药物配置动力学的变化.本文针对生理药物动力学的特点,利用模糊控制模型,并结合生理药物动力学,给出其了动态输出反馈控制方法. In clinical and preclinical study, determine the allowed maximum dose level can avoid the toxicity caused by chemical medicine. By establishing the blood flow restricted compartment model, the prediction of drug operative period in human and the change of pharmacokinetic can be achieved. On the basis of the feature of pharmacokinetic, a class of output feedback controller based on the fuzzy model is presented in the paper.
出处 《生物数学学报》 CSCD 北大核心 2006年第3期395-400,共6页 Journal of Biomathematics
关键词 生理药物动力学 生理模型 隔室模型 T-S模糊模型 动态输出反馈 Pharmacokinetic Physiological model Compartment model T-S fuzzy model Output feedback
  • 相关文献

参考文献7

二级参考文献27

  • 1朱凤艳,吉中孚.氯氮平的药代动力学及其影响因素[J].临床精神医学杂志,1995,5(4):245-247. 被引量:6
  • 2丁勇.血流限速生理药动学模型的平均稳态浓度[J].中国医学物理学杂志,1996,13(3):146-148. 被引量:2
  • 3杨静化,宋祥珍.预报静脉血药浓度的药动学模型C[J].中国药科大学学报,1997,28(1):59-62. 被引量:5
  • 4滕人黎 胡晋 顾学裘.鹤草酚大鼠生理药物动力学模型研究[J].沈阳药学院学报,1987,4(2):143-148.
  • 5[1]Pepine C J, Wolff AA. A controlled trial with a novel anti-ischemic agent, ranolazine, in chromic stable angina pectoris that responsive to conventional antianginal agents. Ranolazine study group [J]. Am J Cardiol , 1999,84: 46-50.
  • 6[2]Bagger JP, Botker HE, Thomassen A, et al. Effects of ranolazine on ischemic threshold coronary sinus blood flow, and myocardial metabolism in coronary artery disease [J]. Cardiovasc Drugs Ther,1997,11:47-84.
  • 7[3]Henon WJ, Eadie J, Penman A D. Estimation of ranolazine and eleven phase I metabolites in human plasma by liquid chromatographyatmospheric pressure chemical ionisation mass spectrometry with selected-ion monitoring[J]. J Chromatogr A, 1995,712: 55-60.
  • 8[4]McCormack JG, Barr RL, Wolff AA, et al. Ranolazine stimulates glucose oxidation in normoxic ischemic and reperfusion ischemic rat hearts[J]. Circulation, 1996,93:135-142.
  • 9[5]Wang J X, Maruyama K, Murakami M, et al. Antianginal effects of ranolazine in various experimental models of angina [J].Arzneimittelf orschung , 1999,49:193-199.
  • 10[6]XD Liu, L Xie, Y Liang, et al. Gender difference in ranolazine pharmacokinetics in rats[J]. Eur J Drug Metabo Pharmacokinet,2003,28:119-123.

共引文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部